[Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol].

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Revista de neurologia Pub Date : 2024-09-16 DOI:10.33588/rn.7906.2024086

C Arenas-Cabrera, P Cabezudo-García, R Calvo-Medina, B Galeano-Bilbao, P Martínez-Agredano, J Ruiz-Giménez, J J Rodríguez-Uranga, P Quiroga-Subirana

{"title":"[Advances and guidance in the treatment of drug-resistant epilepsy: a review by the Andalusian Epilepsy Society of the new drugs cenobamate, fenfluramine and cannabidiol].","authors":"C Arenas-Cabrera, P Cabezudo-García, R Calvo-Medina, B Galeano-Bilbao, P Martínez-Agredano, J Ruiz-Giménez, J J Rodríguez-Uranga, P Quiroga-Subirana","doi":"10.33588/rn.7906.2024086","DOIUrl":null,"url":null,"abstract":"<p><p>This review, conducted by the Andalusian Epilepsy Society, provides an update on recent advances in the treatment of drug-resistant epilepsy, focusing on three new anti-seizure drugs: cenobamate, fenfluramine and cannabidiol. These emerging drugs offer new therapeutic alternatives for patients with drug-resistant focal epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome. The primary objective of this review is to provide healthcare professionals with an up-to-date overview of the efficacy, safety and potential clinical applications of these treatments, backed by the latest evidence. In addition to reviewing the available clinical evidence, the document addresses essential practical considerations for the implementation of these drugs in routine clinical practice, including aspects such as their dosage, drug interactions, and management of their side-effects. With this review, the Andalusian Epilepsy Society aims to contribute to improving the care for and quality of life of patients with drug-resistant epilepsy and their families.</p>","PeriodicalId":21281,"journal":{"name":"Revista de neurologia","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469102/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de neurologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33588/rn.7906.2024086","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This review, conducted by the Andalusian Epilepsy Society, provides an update on recent advances in the treatment of drug-resistant epilepsy, focusing on three new anti-seizure drugs: cenobamate, fenfluramine and cannabidiol. These emerging drugs offer new therapeutic alternatives for patients with drug-resistant focal epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome. The primary objective of this review is to provide healthcare professionals with an up-to-date overview of the efficacy, safety and potential clinical applications of these treatments, backed by the latest evidence. In addition to reviewing the available clinical evidence, the document addresses essential practical considerations for the implementation of these drugs in routine clinical practice, including aspects such as their dosage, drug interactions, and management of their side-effects. With this review, the Andalusian Epilepsy Society aims to contribute to improving the care for and quality of life of patients with drug-resistant epilepsy and their families.

查看原文本刊更多论文

[耐药性癫痫治疗的进展与指导：安达卢西亚癫痫协会对新药仙诺巴马特、芬氟拉明和大麻二酚的审查]。

这篇由安达卢西亚癫痫协会撰写的综述介绍了治疗耐药性癫痫的最新进展，重点关注三种新型抗癫痫药物：仙诺巴马特、芬氟拉明和大麻二酚。这些新兴药物为耐药性局灶性癫痫、德拉维特综合征和伦诺克斯-加斯豪特综合征患者提供了新的治疗选择。本综述的主要目的是以最新证据为支撑，为医疗保健专业人员提供有关这些疗法的疗效、安全性和潜在临床应用的最新概述。除了回顾现有的临床证据外，本文件还讨论了在常规临床实践中使用这些药物的基本实际注意事项，包括用药剂量、药物相互作用和副作用管理等方面。安达卢西亚癫痫协会希望通过本综述，为改善耐药性癫痫患者及其家属的护理和生活质量做出贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊